Compare Match Group Inc (MTCH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs TG Therapeutics Inc — how do they compare? Match Group Inc trades at $39.02 (market cap $9.10B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Match Group Inc and TG Therapeutics Inc are close in size by market cap, and Match Group Inc pays a 2.05% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MTCH | TGTX | |
|---|---|---|
Market Cap | $9.10B | $8.26B |
Sector | Media | Health |
52-Week High | $40.29 | $59.06 |
52-Week Low | $28.90 | $26.39 |
Enterprise Value | $12.05B | $8.50B |
Dividend Yield | 2.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $38.75, down 1.02% today, near the analyst low target of $38.00. The stock shows a bullish technical signal with strong moving average support, while oscillators remain neutral. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat estimates. Revenue growth is stable at $3.5B annually, with net income margins improving to 17.59% in 2025. Positive news highlights Tinder's turnaround efforts and Hinge's growth, with a dividend scheduled for July 2026.
Outlook is cautiously optimistic with a consensus price target of $41.63, implying ~7% upside. Strengths include high gross margins (73.8%) and consistent cash flow growth. Risks involve high debt ($3.85B) and Tinder's user declines offset by pricing. Analyst sentiment is bullish (53% Buy), but execution on user engagement remains critical for sustained gains.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
